PROCEPT BioRobotics (PRCT) Q3 2026 earnings review
Procept BioRobotics holds its 2026 plan, but new installations slow
Procept BioRobotics, a maker of waterjet surgical robots for prostate disease, grew steadily this quarter while leaving a steep climb for year-end. Revenue rose 18% from a year ago and US surgeries increased 22%, lifted by higher handpiece prices and international demand. Chief executive Larry Wood kept the full-year outlook unchanged, which by our math requires revenue growth to jump above 60% in the fourth quarter.
| Revenue | $98.3M +18% from a year ago |
|---|---|
| US procedures | 13,400 +22% from a year ago |
| Gross margin | 66.3% 64.8% a year ago |
| Full-year revenue outlook | Unchanged $390M–$410M (middle: +30%) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because cleaner profit margins and faster robot upgrades were offset by fewer new hospital installations and a demanding fourth-quarter target. Gross margin held at 66% without last quarter's tariff refund, and hospitals bought 20 replacement HYDROS robots. On the other hand, new US robot additions fell 28% from a year ago to 42 systems, and surgeries per machine dropped 9% by our math.
The question now is whether upgrading older machines to the new HYDROS robot actually creates new surgeries or just shifts patients between hospitals. If the upgrades add new volume and sales reps close year-end equipment deals, the company can hit its fourth-quarter profit and revenue targets; otherwise, it risks missing its annual plan for a second straight year. Fourth-quarter procedure volume and system sales will settle it.
🐂 Bull Case
Hospitals Are Upgrading Older Robots Faster
Procept BioRobotics makes robotic systems that use a heat-free waterjet, a treatment called Aquablation, to remove prostate tissue. Chief executive Larry Wood is "accelerating our replacement cycle to transition AquaBeam systems to HYDROS", its newer AI-powered surgical robot.
The medical-device maker delivered 20 replacement HYDROS units in the United States this quarter, up from 14 in the second quarter and 2 in the first. That brings nine-month upgrades to 36 systems, nearly reaching the company's full-year target of about 40 with one quarter left.
What to watch: fourth-quarter replacement deliveries and average system prices. If hospitals keep trading in older machines without deeper price discounts, upgrades will support equipment revenue next year.
Higher Prices Lifted Gross Margin Without One-Offs
Last quarter, Procept BioRobotics reported a 66% gross margin, but a $2.9 million tariff refund added 3.1 percentage points by our math. In the third quarter, the surgical-robotics group held gross margin at 66.3%, up 1.5 percentage points from a year ago, with no reported one-time benefit.
- Cost of sales: 33.7% of revenue, down 1.5 percentage points from a year ago
- US handpiece average selling price: about $3,570, up 12% from a year ago
- New US HYDROS system average price: about $495,000, above the $480,000–$490,000 second-half outlook
- US handpieces sold: 106% of procedures, up from 98% last quarter
By our math, underlying gross margin rose 3.3 percentage points from last quarter's clean 62.9% level because higher prices on single-use handpieces and new robots offset lower-priced trade-in deals. What to watch: fourth-quarter gross margin against the 65% full-year plan, where a drop below 63% would show replacement discounts are hurting profitability.
International Sales Regained Speed
Sales outside the United States are a key part of the full-year revenue plan, which calls for $50 million to $51 million in international sales. After slowing to 15.4% growth in the second quarter, international revenue rose 32.4% from a year ago to $12.5 million in the third quarter.
Both overseas equipment sales ($4.5 million, up 32.8%) and handpiece sales ($7.0 million, up 31.2%) picked up speed. What to watch: fourth-quarter international revenue, which by our math still needs to reach at least $15.3 million, up 57% from a year ago, to hit the full-year target.
Positives this quarter didn't test
Two commercial initiatives got no new numbers in the earnings release because management typically updates them on the conference call.
- Dedicated launch team: aimed at supporting 100% of new HYDROS hospital launches by year-end, up from about 40% in the second quarter; the fourth-quarter call will show if the team hit its year-end goal.
- Direct-to-patient marketing: television, radio and digital ads running in 18 US markets to bring patients into clinics; fourth-quarter procedure volume will show whether the ads are lifting surgeries per machine.
🐻 Bear Case
The Unchanged Outlook Requires a Steep Fourth-Quarter Jump
"As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan," chief executive Larry Wood said. Procept BioRobotics kept its 2026 revenue outlook at $390 million to $410 million even after third-quarter revenue grew 18.0% from a year ago to $98.3 million, down from 19.3% growth in the second quarter.
Keeping the full-year target unchanged leaves a heavy lift for the final three months of the year. By our math, the middle of the range requires $124.1 million in fourth-quarter revenue, a 62.4% jump from a year ago and a 26.2% rise from the third quarter. Even the bottom of the range requires $114.1 million, or 49.3% growth from a year ago.
Part of the year-on-year jump comes from an easy comparison, because fourth-quarter 2025 handpiece sales ($34.0 million) fell when the US company stopped offering quarter-end bulk discounts. Still, adding $16 million to $26 million of revenue in a single quarter is a steep climb when new US robot placements are slowing. What to watch: fourth-quarter total revenue against the $114.1 million floor needed to avoid a second annual revenue miss in two years.
Surgeries Per Machine Fell as New Placements Slowed
Procept BioRobotics grows by placing robots in new hospitals and getting surgeons to use each machine more often. In the third quarter, the US installed base grew 31.4% from a year ago to 858 systems, while US procedures rose 21.8% to about 13,400.
- Procedures per average US system: 16.0, down 9.2% from 17.6 a year ago by our math
- New US install-base placements: 42 systems, down 27.6% from 58 a year ago
- US system revenue: $24.7 million, unchanged from a year ago
Because procedures are growing slower than the machine count, average surgeries per robot fell for a third straight quarter. Meanwhile, shifting sales reps toward replacement deals coincided with the smallest number of new hospital placements since early 2025, leaving US equipment revenue flat. What to watch: fourth-quarter US procedures, which by our math must reach 15,300 to 17,300 (17.2 to 19.4 per machine) to hit the full-year plan.
High Overhead Leaves Fourth-Quarter Profit Reliant on Sales
The urology company plans to reach positive adjusted EBITDA, a measure of operating profit before stock pay, depreciation, interest and taxes, in the fourth quarter. In the third quarter, total operating expenses rose 19.9% from a year ago to $92.5 million on "continued investment in our people, product development, clinical studies and sales and marketing programs".
Selling, general and administrative costs (sales reps, marketing and overhead) rose 3.0 percentage points of revenue from a year ago to 73.8%, while research and development fell 1.5 percentage points to 20.4%. That widened the third-quarter adjusted EBITDA loss to $9.8 million from $7.4 million a year ago, and the net loss to $26.5 million.
What to watch: fourth-quarter adjusted EBITDA, which by our math must swing to a profit of $4.3 million to $9.3 million to meet the full-year loss outlook of $35 million to $30 million.
Risks this quarter didn't answer
Two standing external risks and one clinical trial milestone had no new data in the third-quarter release.
- Prostate artery embolization (PAE) competition and physician fee cuts: whether rival minimally invasive treatments or lower doctor reimbursement are hurting older AquaBeam sites requires conference-call commentary.
- WATER IV prostate cancer trial: Wood remains "excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027", so the clinical read arrives next spring.
💲 Other KPIs
Total cash fell by $9.5 million from last quarter, a slower cash drain than the $17.7 million decline in the second quarter and $40.9 million drop in the first. Procept BioRobotics holds $218.4 million in cash and $3.0 million in restricted cash against $51.8 million in long-term debt.
Uncollected customer bills dipped by $2.6 million from last quarter after jumping from $83.5 million at year-end to $107.6 million in June. Compared with a year ago, receivables are still up 24.3%, outpacing the 18.0% rise in third-quarter revenue and tying up cash.
Stockpiled systems and handpieces rose by $4.3 million from last quarter and $10.7 million from the end of 2025, an increase of 15.2% over nine months. Management is building inventory ahead of the seasonally large fourth quarter.
🔮 Guidance
Unchanged. The surgical-robotics maker still plans for 27% to 33% full-year revenue growth. By our math, hitting the $400 million middle of the range requires $124.1 million in the fourth quarter, up 62.4% from a year ago against a depressed comparison quarter.
Unchanged. After cutting this target from 60,000–64,000 last quarter, management kept its forecast for 25% to 29% full-year procedure growth. By our math, that leaves 15,300 to 17,300 surgeries for the fourth quarter, or 33.6% growth from a year ago at the middle of the range.
Unchanged. Nine-month gross margin sits at 65.8% after reaching 66.3% in the third quarter. By our math, the full-year target of roughly 65% allows fourth-quarter gross margin to step down to about 63.3% at the middle of the revenue range.
Unchanged. With the nine-month adjusted EBITDA loss at $39.3 million, the full-year plan requires a fourth-quarter profit of $4.3 million to $9.3 million ($6.8 million at the middle of the range), or a 5.5% margin on implied fourth-quarter sales by our math.
Cut. In its reconciliation table, the company widened its expected full-year GAAP net loss by $1.8 million because it expects $1.0 million more in depreciation, $0.2 million more in stock pay, and $0.6 million less in net interest income. By our math, that leaves a $10.3 million net loss for the fourth quarter.
❓ Key Questions
Why did new US system placements drop to 42?
Greenfield placements adding to the US installed base fell 28% from a year ago while replacement sales rose to 20. Investors need to know whether sales reps are trading new hospital wins for easier replacement upgrades.
Are HYDROS upgrades creating new surgeries or moving them?
Average procedures per US system fell 9% from a year ago to 16.0 even as HYDROS upgrades reached 36 this year. Management has not disclosed procedures per machine split between HYDROS and older AquaBeam units.
What drives the implied 57% fourth-quarter international growth?
Nine-month revenue outside the US is $34.7 million, leaving $15.3 million to $16.3 million in the fourth quarter to meet the $50 million to $51 million full-year target crafted last quarter.
How much did hospital restocking boost third-quarter handpiece sales?
US handpieces sold jumped to 106% of procedure volume from 98% in the second quarter and 95% in the first. If hospitals bought ahead, fourth-quarter consumable orders could lag procedure growth.